| HON |
Report |
Q2 Revenue |
IN-LINE |
pred ~$9.64B vs. cons $9.581B |
MEDIUM |
| HON |
Report |
Q2 Adjusted EPS |
BEAT |
pred ~$4.98 vs. cons $4.918 |
MEDIUM |
| HON |
Report |
Q2 Segment Margin |
IN-LINE |
pred ~19.05% vs. cons 18.98% |
MEDIUM |
| HON |
Guide |
2H 2026 Honeywell Technologies sales |
UNKNOWN |
guide ~$10.1B-$10.3B vs. cons UNVERIFIED |
LOW |
| HON |
Guide |
FY 2026 Honeywell Technologies adjusted EPS |
UNKNOWN |
guide ~$7.90-$8.30 vs. cons UNVERIFIED |
LOW |
| HON |
Guide |
PA&T / IA qualitative outlook |
UNCHANGED |
reaffirm 2H PA&T acceleration and IA recovery; no reliable qualitative consensus |
MEDIUM |
| HON |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
MEDIUM |
| HON |
Return |
5-day cumulative residual |
-4.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained guide implies insufficient forward upside |
MEDIUM |